Immunocore Holdings plc IMCR

Company Overview

Immunocore Holdings plc is a commercial-stage biotechnology company focused on developing and commercializing T cell receptor (TCR)-based immunotherapies for cancer, infectious diseases, and autoimmune conditions. The company operates within the biotechnology and immuno-oncology industries and is best known for its proprietary ImmTAX platform, which engineers soluble TCR molecules designed to recognize intracellular disease-associated antigens and redirect T cells to eliminate target cells. Immunocore’s primary commercial product is KIMMTRAK (tebentafusp-tebn), approved in multiple markets for the treatment of unresectable or metastatic uveal melanoma in HLA-A*02:01-positive adult patients. Revenue is primarily generated from product sales, collaboration agreements, licensing arrangements, and research partnerships.

The company was founded in the United Kingdom as a spinout from Oxford University research and evolved from an early-stage immunotherapy developer into a publicly traded biotechnology company listed on Nasdaq under the ticker IMCR. Immunocore’s strategic positioning is centered on its specialized TCR platform technology, which differs from conventional antibody-based therapies by targeting intracellular proteins presented on cell surfaces through peptide-HLA complexes. This approach has positioned the company as a notable participant in the emerging TCR therapeutics field, particularly in solid tumors where conventional immunotherapies have shown more limited efficacy.